| HOME >> MEDICINE >> TECHNOLOGY |
Table 26: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis 76
Table 27: Mean Percentage Change in BMD in Postmenopausal Women with Osteoporosis 76
Table 28: Osteoporosis Therapeutics Market, Phase III and Regulatory Filed Pipeline, 2011 84
Table 29: Osteoporosis Therapeutics Market, Phase II Pipeline, 2011 85
Table 30: Osteoporosis Therapeutics Market, Phase I Pipeline, 2011 86
Table 31: Osteoporosis Therapeutics Market, Pre-clinical and Discovery Phase Pipeline, 2011 87
Table 32: Osteoporosis Therapeutics Market, Global, Most Promising Drugs in Clinical Development, 2011 90
Table 33: Osteoporosis Therapeutics, Global, Clinical Trials, 2011 102
Table 34: Osteoporosis Therapeutics, Global, Clinical Trials by Phase, 2011 103
Table 35: Osteoporosis Therapeutics, Global, Clinical Trials by Status of Development, 2011 104
Table 36: Osteoporosis Therapeutics, Global, Prominent Sponsors, 2011 105
Table 37: Osteoporosis Therapeutics, Global, Overall Sponsors, 2011 106
Table 38: Osteoporosis Therapeutics, Global, Top Ten Companies by Phase, 2011 107
Table 39: Amgen Inc.– Osteoporosis Pipeline, 2011 114
Table 40: Astellas Pharma, Inc. – Osteoporosis Pipeline, 2011 116
Table 41: EffRx, Inc. – Osteoporosis Pipeline, 2011 117
Table 42: Merck & Co., Inc.– Osteoporosis Pipeline, 2011 118
Table 43: Novartis AG – Osteoporosis Pipeline, 2011 120
Table 44: Osteologix,Inc. – Osteoporosis Pipeline, 2011 121
Table 45: Pfizer Inc. .– Osteoporosis Pipeline, 2011 125
Table 46: Radius Health Inc. – Osteoporosis Pipeline, 2011 126
Table 47: Tarsa Inc. – Osteoporosis Pipeline, 2011 126
Table 48: ZydusCadila Inc. – Osteoporosis Pipeline, 2011 129
Table 49: Osteopor
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |